Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Current Deferred Revenue of $288000.0 for Q2 2025, little changed year-over-year from $288000.0 in Q2 2024, and little changed quarter-over-quarter from $288000.0 in Q1 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $288000.0 for Q2 2025.
- In Q2 2025, Current Deferred Revenue changed 0.0% year-over-year to $288000.0; the TTM figure through Jun 2025 stood at $288000.0 (changed 0.0% YoY), while the FY2024 annual figure was $288000.0, changed 0.0% from the prior year.
- Current Deferred Revenue for Q2 2025 stood at $288000.0, roughly flat from $288000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $289000.0 in Q4 2021, with the low at $288000.0 in Q1 2021.
- The 5-year median for Current Deferred Revenue is $288000.0 (2021), against an average of $288055.6.
- The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue retreated 3.99% in 2021, then changed 0.0% in 2022.
- Viridian Therapeutics, Inc.\DE's Current Deferred Revenue stood at $289000.0 in 2021, then slipped by 0.35% to $288000.0 in 2022, then changed by 0.0% to $288000.0 in 2023, then changed by 0.0% to $288000.0 in 2024, then changed by 0.0% to $288000.0 in 2025.
- Business Quant data shows VRDN's Current Deferred Revenue at $288000.0 in Q2 2025, $288000.0 in Q1 2025, and $288000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | 288,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 288,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 288,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Jun 30, 2022 | 288,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Dec 31, 2021 | 289,000.00 |
| Sep 30, 2021 | 288,000.00 |
| Jun 30, 2021 | 288,000.00 |
| Mar 31, 2021 | 288,000.00 |
| Dec 31, 2020 | 301,000.00 |